IL6 and non-small cell lung carcinoma: These results go in line with previous studies highlighting upregulated lncRNA XIST in non-small-cell lung cancer (49), lncRNA MALAT-1, lncRNA HOTAIR (50), miR-155 (51), and IL-6 (52) as upregulated serum BC patient diagnostic biomarkers.